Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited
中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2361)

VOLUNTARY ANNOUNCEMENT
SINOHEALTH UNVEILS ITS 2025 AI COMMERCIALIZATION BUSINESS UPDATE

This announcement is made by Sinohealth Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**", "**we**" and "**our**") on a voluntary basis to update the shareholders of the Company and potential investors on the latest business development of the Group.

The board of directors of the Company is pleased to announce that, as of the date of this announcement, the Company has made significant progress in the commercialization of AI large models and AI agents, with its AI services and products covering a broad range of application scenarios, including marketing, healthcare, pharmacies, and consumer management, and reaching a comprehensive healthcare industry cooperation network spanning "physician, pharmacy, patient":

Marketing

In terms of marketing, we have launched the AI for Marketing Lab and introduced the "Tiangong No. 1 Commercial Agent (天宮一號•商用智能體). It is now providing "+AI" digital intelligent solutions to 182 pharmaceutical companies, enabling them to respond rapidly to changing environments and make efficient, data-driven decisions and actions.

Healthcare

In the aspect of healthcare, leveraging our self-developed "Woodpecker Medical Model" (卓睦鳥醫療大模型), we have implemented the multi-disciplinary joint consultation agent for critical diseases, "iMDT". It has already served 512 hospitals and empowered more than 1,520 clinicians to conduct complicated medical diagnoses, significantly enhancing the quality of multi-disciplinary team (MDT) decisions.

Pharmacies

In the pharmacy sector, our pharmacy agent has already served over 10,993 pharmacies. Utilizing comprehensive industry data, we have developed a matrix of five AI agents for operational insights, products, diseases, memberships, and staff, together with specialized AI tailored to "individuals, families, diseases, and medications", empowering performance at the store level.

Consumer Management

In the scenario of health management, we have created an AI agent matrix covering "individuals, families, diseases, and medications," utilizing a precise user base of over 3 million. This system offers personalized health interventions and risk alerts, establishing a full-cycle management system that includes prevention, screening, and intervention.

The business data disclosed in this announcement demonstrate that the Company has successfully transformed from a data technology service provider into an AI technology service provider. The Company will continue to enhance its integrated capabilities across "data, models, scenarios and ecosystem", and will remain committed to becoming the preferred AI service provider in the healthcare industry.

The Company hereby informs its shareholders and potential investors of its latest business developments. The information contained in this announcement is based on the Company's preliminary assessment and currently available information, and not on any figures or information that have been audited, reviewed, or approved by the Company's auditors. The figures set out in this announcement are provided for illustrative purposes only and do not constitute forward-looking statements or profit forecasts. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 24 December 2025

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.